



Staging and Pathology of Bladder Cancer

Guest Editors:

Prof. Dr. Ke-Hung Tsui

1. Department of Urology, Shuang Ho Hospital, New Taipei City, Taiwan
2. TMU Research Center of Urology and Kidney, Department of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

Prof. Dr. Horng-Heng Juang

Department of Anatomy, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Deadline for manuscript submissions:

closed (15 July 2024)

Message from the Guest Editors

Dear Colleagues,

Bladder cancer has become the ninth most common cancer worldwide, and the sixth most common malignancy in the United States, according to an epidemiologic statistics report published in 2017. Although many tumor markers associated with the development of bladder cancer have been widely reported, the rates of mortality and recurrence of bladder cancer are still high. Bladder cancer usually presents at an early stage, with most patients presenting with Tis or T1 disease and, thus, high recurrence rates. At present, different recurrence rates are observed according to the pathological staging and tumor grading. The reasons for this increase in recurrence, and tumor biology in particular, are poorly understood. Treatment of bladder cancer has evolved in recent years, with several new treatment techniques that lead to improvements in uro-oncology. This Special Issue mainly aims to discuss a collection of basic research and clinical treatments for the early detection, early diagnosis and early treatment of bladder cancer.

Here, we welcome papers outlining tumor biology, diagnostics, and treatment modalities of bladder cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)